North Immunology is joining the reverse-merger pipeline, aiming to bring an atopic dermatitis antibody to clinical development while raising capital through a public listing structure. The company described the reverse merger as its chosen path to advancing toward clinic, aligning with a market moment that has seen sentiment for longer-duration immunology programs improve. The move also adds to a broader flurry of reverse deals that have been structured around mid-stage assets and near-term clinical readouts, in contrast to earlier years when such structures carried greater skepticism. For investors, the listing route emphasizes how capital access is being re-engineered to support development timelines and reduce dilution pressure for late-stage clinical execution.